Standardization of C-Peptide Measurements in Urine by Method Comparison with Isotope-Dilution Mass Spectrometry

Fierens, Colette; Stöckl, Dietmar; Baetens, Dimitri; Leenheer, A.P. De; Thienpont, Linda M.

doi:10.1373/49.6.992

Cited by 24 publications

(22 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Not recommended to measure the insulin level are tissue samples of liver, brain or kidney [66]. Coe reported Table 1 Reference levels of relevant peptides in blood (I/C-ratio=molar ratio of insulin to C-peptide; insulin: μU/ml×6=pmol/l, C-peptide: μg/ l×0.28=nmol/l, proinsulin: ng/l×0.11=pmol/l) Reference range in urine for non-diabetics 2.76-6.9 μU/ml [101,102,147,148] 40-150 μg/l, 32-165 μg/l, 10-120 μg/l [101,102,147,148] that insulin and C-peptide rarely penetrate the blood-vitreous barrier [67]. In one case of an insulin intoxication, Winston et al [68] measured vitreous insulin in a concentration of 31 μU/ml but there are no reference data or validated methods for VF and cerebrospinal fluid.…”

Section: Insulin In Other Matricesmentioning

confidence: 99%

Disorders of glucose metabolism: post mortem analyses in forensic cases–part II

2010

View full text Add to dashboard Cite

In continuation to part I, a literature review is presented concerning biochemical problems of forensic post mortem cases of unclear hyperglycaemia or hypoglycaemia. Clinical parameters for this purpose were recently reviewed. Particular attention was paid to the detection of diabetic ketoacidosis, of hyperosmolar coma, insulinoma, insulin-induced or oral diabetic-induced hypoglycaemia. The second part of the review discusses the analytes ketone bodies, synthetic insulins, human insulin, C-peptide, proinsulin and insulin antibodies. Special interest is given to post mortem matrices for those analytes to reference concentrations, stability data, analytic interferences and analytical procedures which should be used in toxicological laboratories willing to detect diabetic metabolism disorders after death.

show abstract

Section: Insulin In Other Matricesmentioning

confidence: 99%

Disorders of glucose metabolism: post mortem analyses in forensic cases–part II

2010

View full text Add to dashboard Cite

show abstract

“…More recently this approach has been used in standardized assays for larger peptides in serum such as 3 kDa thymosin a1 (LLOQ 0.5 ng ml −1 (Tuthill et al 2000) CV < 10%) and for small proteins like the 10 kDa recombinant protein rK5 (LOQ 100 ng ml −1 in monkey serum (Ji et al 2003) and later 10 ng ml −1 in human serum (Ji et al 2004), CV of 3%). The structural specificity of MS/MS allows better analyte discrimination than immunoassays: particular forms of insulin and its fragments can be selectively detected (Kippen et al 1997), and in fact MS/MS is now used as a reference against which to standardize different immunoassays for C-peptide (Fierens et al 2003).…”

Section: Technology Platforms For Targeted Proteomics Of Candidate Mamentioning

confidence: 99%

Candidate‐based proteomics in the search for biomarkers of cardiovascular disease

Anderson¹

2005

The Journal of Physiology

346

249

View full text Add to dashboard Cite

The key concept of proteomics (looking at many proteins at once) opens new avenues in the search for clinically useful biomarkers of disease, treatment response and ageing. As the number of proteins that can be detected in plasma or serum (the primary clinical diagnostic samples) increases towards 1000, a paradoxical decline has occurred in the number of new protein markers approved for diagnostic use in clinical laboratories. This review explores the limitations of current proteomics protein discovery platforms, and proposes an alternative approach, applicable to a range of biological/physiological problems, in which quantitative mass spectrometric methods developed for analytical chemistry are employed to measure limited sets of candidate markers in large sets of clinical samples. A set of 177 candidate biomarker proteins with reported associations to cardiovascular disease and stroke are presented as a starting point for such a 'directed proteomics' approach.

show abstract

“…Isotope dilution assays (IDAs) (Barr et al, 1996) use isotope-labeled internal standards (IS) for absolute quantification by mass spectrometry in most biological mediums: blood Stocklin et al, 1997;Satterfield et al, 2003), urine (Fierens et al, 2000(Fierens et al, , 2003, tissue (Desiderio & Zhu, 1998;Barnidge et al, 2003;Peng et al, 2004), and cell culture (Gerber et al, 2003). Optimally, a synthetic version of the targeted tryptic peptide would be used with heavy isotopes of 2 H, 13 C, and 15 N for differentiation by MSMS (Gerber et al, 2003).…”

Section: B Protein Quantificationmentioning

confidence: 99%

Neuroproteomics in neurotrauma

Ottens

Kobeissy

Golden

et al. 2006

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Neurotrauma in the form of traumatic brain injury (TBI) afflicts more Americans annually than Alzheimer's and Parkinson's disease combined, yet few researchers have used neuroproteomics to investigate the underlying complex molecular events that exacerbate TBI. Discussed in this review is the methodology needed to explore the neurotrauma proteome-from the types of samples used to the mass spectrometry identification and quantification techniques available. This neuroproteomics survey presents a framework for large-scale protein research in neurotrauma, as applied for immediate TBI biomarker discovery and the far-reaching systems biology understanding of how the brain responds to trauma. Ultimately, knowledge attained through neuroproteomics could lead to clinical diagnostics and therapeutics to lessen the burden of neurotrauma on society.

show abstract

Standardization of C-Peptide Measurements in Urine by Method Comparison with Isotope-Dilution Mass Spectrometry

Abstract: The accurate antenatal prediction of fetal lung maturity (FLM) based on results from amniotic fluid samples is of

Cited by 24 publications

References 8 publications

Disorders of glucose metabolism: post mortem analyses in forensic cases–part II

Disorders of glucose metabolism: post mortem analyses in forensic cases–part II

Candidate‐based proteomics in the search for biomarkers of cardiovascular disease

Neuroproteomics in neurotrauma

Contact Info

Product

Resources

About